HIV-1 genetic variation and drug resistance development. (Q30354857)

20 June 2017

HIV-1 genetic variation and drug resistance development. (English)

1 reference

20 June 2017

1 reference

2

0 references

author name string

Sarah Megens

series ordinal

1

1 reference

20 June 2017

1 November 2013

1 reference

Expert Review of Anti-infective Therapy

20 June 2017

1 reference

20 June 2017

11

1 reference

20 June 2017

11

1 reference

20 June 2017

1159-1178

1 reference

Simian retroviruses in African apes

20 June 2017

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Global trends in molecular epidemiology of HIV-1 during 2000-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

HIV Genetic Diversity and Drug Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

The evolution of drug resistance interpretation algorithms: ANRS, REGA and extension of resistance analysis to HIV-1 group O and HIV-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Raltegravir and etravirine are active against HIV type 1 group O.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Treatment response and drug resistance in patients infected with HIV type 1 group O viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Enfuvirtide is active against HIV type 1 group O.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Natural polymorphisms of integrase among HIV type 1-infected South African patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

The SnoB study: frequency of baseline raltegravir resistance mutations prevalence in different non-B subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

HIV-1 phenotypic reverse transcriptase inhibitor drug resistance test interpretation is not dependent on the subtype of the virus backbone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Impact of amino acid variations in Gag and protease of HIV type 1 CRF01_AE strains on drug susceptibility of virus to protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

HIV-1 proteases from drug-naive West African patients are differentially less susceptible to protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Susceptibility to antiretroviral drugs of CRF01_AE, CRF02_AG, and subtype C viruses from untreated patients of Africa and Asia: comparative genotypic and phenotypic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Catalytic efficiency and vitality of HIV-1 proteases from African viral subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Amplification of the effects of drug resistance mutations by background polymorphisms in HIV-1 protease from African subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

In vitro hypersusceptibility of human immunodeficiency virus type 1 subtype C protease to lopinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Mutations other than 103N in human immunodeficiency virus type 1 reverse transcriptase (RT) emerge from K103R polymorphism under non-nucleoside RT inhibitor pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Drug resistance mutation profile and accumulation kinetics in human immunodeficiency virus-positive individuals infected with subtypes B and F failing highly active antiretroviral therapy are influenced by different viral codon usage patterns.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Synonymous genetic polymorphisms within Brazilian human immunodeficiency virus Type 1 subtypes may influence mutational routes to drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Distinct resistance mutation and polymorphism acquisition in HIV-1 protease of subtypes B and F1 from children and adult patients under virological failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Effect of human immunodeficiency virus type 1 protease inhibitor therapy and subtype on development of resistance in subtypes B and G.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Characterization of nevirapine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Trends in Genotypic HIV-1 Antiretroviral Resistance between 2006 and 2012 in South African Patients Receiving First- and Second-Line Antiretroviral Treatment Regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Signature nucleotide polymorphisms at positions 64 and 65 in reverse transcriptase favor the selection of the K65R resistance mutation in HIV-1 subtype C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Impact of HIV type 1 genetic subtype on the outcome of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Viral load and CD4 cell response to protease inhibitor-containing regimens in subtype B versus non-B treatment-naive HIV-1 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Impact of baseline polymorphisms in RT and protease on outcome of highly active antiretroviral therapy in HIV-1-infected African patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Polymorphism in Gag gene cleavage sites of HIV-1 non-B subtype and virological outcome of a first-line lopinavir/ritonavir single drug regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Comparative response of African HIV-1-infected individuals to highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Evaluating immunologic response and clinical deterioration in treatment-naive patients initiating first-line therapies infected with HIV-1 CRF01_AE and subtype B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Performance of ViroSeq HIV-1 Genotyping System in routine practice at a Belgian clinical laboratory

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: Impact of resistant minority variants on efficacy of low genetic barrier drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Integrase polymorphism and HIV-1 group O diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Raltegravir-Based Regimens Are Effective in HIV-1 Group O–Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

The Calculated Genetic Barrier for Antiretroviral Drug Resistance Substitutions Is Largely Similar for Different HIV-1 Subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

HIV-1 protease mutation 82M contributes to phenotypic resistance to protease inhibitors in subtype G

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

HIV-1 Subtype and Virological Response to Antiretroviral Therapy: A Confirmatory Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Effect of HIV Type 1 Subtype on Virological and Immunological Response to Combination Antiretroviral Therapy: Evidence for a More Rapid Viral Suppression for Subtype A Than Subtype B-Infected Greek Individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

Short Communication: Non-B HIV Type 1 Subtypes: Replicative Capacity and Response to Antiretroviral Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2013.844649

10.1586/14787210.2013.844649

21 January 2018

Identifiers

DOI

1 reference

20 June 2017

1 reference

PubMed ID

24151833